SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

l	OMB Number:	3235-0287						
l	Estimated average burden							
l	hours per response:	0.5						

Sectio obligat	this box if no k n 16. Form 4 or ions may conti tion 1(b).		STAT		ed pur	suant	to See	ction 16(	e Investme	Secur	itie	s Exchan	ige Ac	ct of 19	-	SHIP	Estim	3 Numbe nated av s per res	verage burde	3235-0287 m 0.5
1. Name and Address of Reporting Person <sup>*</sup> Collard Craig A						2. Issuer Name and Ticker or Trading Symbol <u>HERON THERAPEUTICS, INC. /DE/</u> HRTX ]								(Ch	telationship o eck all applic X Director	able)	0	10% O	wner	
(Last) (First) (Middle) 4242 CAMPUS POINT COURT, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 04/03/2024									below)	(give title	ve title Other (specify below) f Executive Officer			
(Street) SAN DIEGO CA 92121					- 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	<ul> <li>Individual or Joint/Group Filing (Check Applicable ine)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>					
(City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to Satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Trans Date						a, Transaction Code (Instr		4. Securities Acquired ( Disposed Of (D) (Instr. 3		d (A) or	5. Amour Securities Beneficia Owned Fe	5. Amount of Securities Beneficially Owned Following Reported		vnership : Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
Common Stock			3/2024			Code	• v		Amount	(U)		Price	Transaction(s) (Instr. 3 and 4)		D		(1150.4)			
1. Title of Derivative         2.         3. Transaction         3A. Derivative           Security         Conversion         Date         Execut           Security         or Exercise         (Month/Day/Year)         if any			3A. Deemed Execution I	Deriva (e.g.,   <sup>d</sup>	ative Securities Acqu buts, calls, warrants, 4. 5. Number			luired,	Exerc	CO isal	onvertil	, or Benefic ble securiti 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		ficially rities) Amount s Security	y Owned t 8. Price of Derivative Security (Instr. 5) 8. Price of derivati Security Benefic Owned Followin Reporte Transac (Instr. 4)		re es ally g d ion(s)	D 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able		cpiration ate	Title		Number of Shares					

Explanation of Responses:

\$0.00

Restricted Stock Units

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

04/03/2024

2. The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

62,500

(2)

/s/Kathryn Lester Attorney-in- fact for Craig Collard	04/05/2024			
** Signature of Reporting Person	Date			

**\$0.00** 

187,500

D

62,500

Common Stock

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

М

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## **POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints Kathryn Lester, with full power of substitution, as the undersigned's true and lawful attorney-infact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Heron Therapeutics, Inc., (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of April, 2024.

/s/ Craig Collard Craig Collard

[Signature Page to Limited Power of Attorney]